CARLSBAD, Calif.--(BUSINESS WIRE)--Nalu Medical Inc. (“Nalu”) revealed significant findings from a landmark clinical trial evaluating the Nalu Peripheral Nerve Stimulation (PNS) System utilizing their ...

CARLSBAD, Calif., August 06, 2025--(BUSINESS WIRE)--Nalu Medical, Inc., a leader in miniaturized neuromodulation therapies for chronic neuropathic pain, is pleased to announce that CareFirst BCBS has ...

CARLSBAD, Calif.--(BUSINESS WIRE)--Nalu Medical, Inc. (“Nalu”), a Carlsbad, California-based neurostimulation company that has miniaturized neurostimulation implants for the management of chronic ...

1-year results include the following highlights (N=61)1: 87% of patients experienced 50% or more pain relief. 69% average pain reduction. 95% of patients reported overall improvement. The publication ...

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. Nalu Medical, Inc. (“Nalu”), a leader in peripheral ...

CARLSBAD, Calif., August 05, 2025--(BUSINESS WIRE)--The results of COMFORT 2, the second Nalu Medical Peripheral Nerve Stimulation (PNS) RCT, were published on July 30th, 2025, in the peer-reviewed ...

CARLSBAD, Calif.--(BUSINESS WIRE)-- Nalu Medical, Inc. (“Nalu”), a Carlsbad, California-based company that has successfully miniaturized neurostimulation implants for the management of chronic ...

(Reuters) -Medical device maker Boston Scientific said on Friday it will buy the remaining equity in privately held Nalu Medical for about $533 million in cash, expanding its portfolio of treatments ...

Nalu Medical – a private company focused on innovative, minimally invasive, and non-opioid solutions for chronic neuropathic pain – recently announced the closing of a $65 million equity financing.

Boston Scientific has acquired Nalu Medical for around $533m, broadening the therapeutic scope of the medtech giant’s neuromodulation portfolio. California-based Nalu’s Neurostimulation System is ...

Nalu Medical – a private company focused on innovative, minimally invasive, and non-pharmacologic solutions for chronic neuropathic pain – announced the closing of an incremental $20 million in equity ...